NetEase, Inc. (NTES)

CTI BioPharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	107,272	105,295	103,468	96,496	87,606	73,667
Revenue Growth (YoY)	1.90%	1.77%	7.23%	10.15%	18.92%	24.35%
Cost of Revenue	40,001	39,488	40,405	43,730	40,635	34,684
Gross Profit	67,271	65,807	63,063	52,766	46,971	38,983
Selling, General & Admin	17,132	18,698	18,869	18,099	16,478	14,076
Research & Development	17,736	17,525	16,485	15,039	14,076	10,369
Operating Expenses	34,868	36,223	35,354	33,138	30,554	24,445
Operating Income	32,403	29,584	27,709	19,629	16,417	14,538
Interest Expense	-598	-598	-884.1	-	-	-
Interest & Investment Income	6,171	5,874	6,311	2,204	4,467	3,209
Currency Exchange Gain (Loss)	242.22	255.43	-133	1,571	-490.48	-3,112
Other Non Operating Income (Expenses)	663.56	602.13	1,054	846.82	710.44	737.17
EBT Excluding Unusual Items	38,881	35,718	34,057	24,250	21,104	15,372
Pretax Income	38,881	35,718	34,057	24,250	21,104	15,372
Income Tax Expense	5,881	5,461	4,700	5,032	4,128	3,042
Earnings From Continuing Operations	33,001	30,256	29,357	19,218	16,976	12,330
Earnings From Discontinued Operations	-	-	-	624.86	-	-
Net Income to Company	33,001	30,256	29,357	19,843	16,976	12,330
Minority Interest in Earnings	-635.94	-558.74	59.33	494.31	-119.35	-267.48
Net Income	32,365	29,698	29,417	20,338	16,857	12,063
Net Income to Common	32,365	29,698	29,417	20,338	16,857	12,063
Net Income Growth	6.83%	0.95%	44.64%	20.65%	39.74%	-43.20%
Shares Outstanding (Basic)	3,191	3,200	3,216	3,263	3,326	3,305
Shares Outstanding (Diluted)	3,220	3,231	3,252	3,296	3,367	3,350
Shares Change (YoY)	-0.94%	-0.66%	-1.33%	-2.12%	0.53%	3.07%
EPS (Basic)	10.14	9.28	9.15	6.23	5.07	3.65
EPS (Diluted)	10.05	9.19	9.05	6.17	5.01	3.60
EPS Growth	7.67%	1.55%	46.69%	23.14%	39.17%	-44.87%
Free Cash Flow	40,912	38,401	33,030	25,609	23,325	23,833
Free Cash Flow Per Share	12.71	11.89	10.16	7.77	6.93	7.12
Dividend Per Share	4.039	3.774	3.637	1.913	1.487	1.024
Dividend Growth	8.76%	3.75%	90.11%	28.71%	45.21%	-46.66%
Gross Margin	62.71%	62.50%	60.95%	54.68%	53.62%	52.92%
Operating Margin	30.21%	28.10%	26.78%	20.34%	18.74%	19.73%
Profit Margin	30.17%	28.20%	28.43%	21.08%	19.24%	16.38%
Free Cash Flow Margin	38.14%	36.47%	31.92%	26.54%	26.63%	32.35%
EBITDA	34,733	32,002	30,764	22,487	19,693	17,996
EBITDA Margin	32.38%	30.39%	29.73%	23.30%	22.48%	24.43%
D&A For EBITDA	2,331	2,418	3,055	2,858	3,276	3,458
EBIT	32,403	29,584	27,709	19,629	16,417	14,538
EBIT Margin	30.21%	28.10%	26.78%	20.34%	18.74%	19.73%
Effective Tax Rate	15.12%	15.29%	13.80%	20.75%	19.56%	19.79%
Advertising Expenses	-	-	-	-	-	3,782

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q